Roivant Sciences Stock
Biopharmaceutical company
Sign up today and learn more about Roivant Sciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Roivant Sciences Stock
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
Investors
Dexcel Pharma
Founders Fund
Lyft, Spotify, Airbnb, Stripe, Anduril Industries, Flexport, Palantir Technologies, Wish, Compass, Zenefits
Novaquest Capital Management
QVT Financial
RTW Investments LLC
Viking Global Investors
Impossible Foods, Moderna Therapeutics, Apeel Sciences, Adaptive Biotechnologies, Arctic Wolf, Talkdesk, Druva, Color, Clip, Iterable
Funding History
| November 2018 | $200M |
|---|---|
| August 2017 | $1.1B |
| July 2016 | $500M |
| May 2014 | $93.0M |
Management
Co-Founder & Chief Executive Officer
Vivek Ramaswamy
Chief Information Officer
Daniel Rothman
Chief Financial Officer
Matthew Gline
Chief Accounting Officer
Rakhi Kumar
Press
ThePharmaLetter - Oct, 31 2019
Sumitomo Dainippon and Roivant confirm strategic allianceglobenewswire - Sep, 6 2019
Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliancefiercebiotech - Feb, 14 2019
Axovant sends off its small molecule team with an epilepsy drug and $100M in funding commitmentsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
